Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.58 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2559504 | 1.00 | MAOB (0.61) | MAOBAPPNR4A2ENPP2MAOA | |
| SCHEMBL12420267 | 0.91 | APP (0.54) | APPENPP2LMNA | |
| SCHEMBL25278599 | 0.85 | MAOB (0.49) | MAOBAPPNR4A2MAOA | |
| SCHEMBL31051012 | 0.85 | MAOB (0.49) | MAOBAPPNR4A2MAOA | |
| SCHEMBL10991891 | 0.84 | MAOB (0.80) | MAOBAPPNR4A2MAOANPC1 | |
| SCHEMBL2559408 | 0.84 | MRGPRX4 (0.48) | MAOBAPPNR4A2ENPP2MAOA | |
| SCHEMBL16687441 | 0.84 | APP (0.47) | APPENPP2LMNA | |
| SCHEMBL2557358 | 0.82 | ENPP2 (0.68) | MAOBAPPENPP2NPC1RAB9A | |
| SCHEMBL2345827 | 0.82 | MAOB (0.61) | MAOBAPPNR4A2ENPP2 | |
| SCHEMBL16687435 | 0.82 | MAOB (0.58) | MAOBAPPENPP2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-20 | — | — | US | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-3535244-A1 | SPIRO-COMPOUNDS AS S1P MODULATORS | Abbvie Deutschland GmbH & Co. KG (DE) | 2019-09-11 | — | — | EP | disclosed |
| EP-3107908-B1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MAOB 104/4885APP 1032/4885NR4A2 3742/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MAOB 104/4885APP 1032/4885NR4A2 3742/4885 |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | MAOB 104/4885APP 1032/4885NR4A2 3742/4885 |
| US-20200055817-A1 | SPIRO-COMPOUNDS AS SIP MODULATORS | S1PR1, STIM1, GIPR | MAOB 2700/4885APP 3089/4885NR4A2 524/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | MAOB 3377/4885APP 735/4885NR4A2 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.